128 related articles for article (PubMed ID: 28238854)
21. Pharmacokinetics and pharmacodynamics of chlorpyrifos and 3,5,6-trichloro-2-pyridinol in rat saliva after chlorpyrifos administration.
Smith JN; Wang J; Lin Y; Klohe EM; Timchalk C
Toxicol Sci; 2012 Dec; 130(2):245-56. PubMed ID: 22874420
[TBL] [Abstract][Full Text] [Related]
22. Impact of repeated nicotine and alcohol coexposure on in vitro and in vivo chlorpyrifos dosimetry and cholinesterase inhibition.
Lee S; Poet TS; Smith JN; Hjerpe AL; Gunawan R; Timchalk C
J Toxicol Environ Health A; 2011; 74(20):1334-50. PubMed ID: 21899407
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic and pharmacodynamic interaction for a binary mixture of chlorpyrifos and diazinon in the rat.
Timchalk C; Poet TS; Hinman MN; Busby AL; Kousba AA
Toxicol Appl Pharmacol; 2005 May; 205(1):31-42. PubMed ID: 15885262
[TBL] [Abstract][Full Text] [Related]
24. Kinetic analysis of the in vitro inhibition, aging, and reactivation of brain acetylcholinesterase from rat and channel catfish by paraoxon and chlorpyrifos-oxon.
Carr RL; Chambers JE
Toxicol Appl Pharmacol; 1996 Aug; 139(2):365-73. PubMed ID: 8806854
[TBL] [Abstract][Full Text] [Related]
25. Development of a non-invasive biomonitoring approach to determine exposure to the organophosphorus insecticide chlorpyrifos in rat saliva.
Timchalk C; Campbell JA; Liu G; Lin Y; Kousba AA
Toxicol Appl Pharmacol; 2007 Mar; 219(2-3):217-25. PubMed ID: 17118418
[TBL] [Abstract][Full Text] [Related]
26. Rat brain CYP2B-enzymatic activation of chlorpyrifos to the oxon mediates cholinergic neurotoxicity.
Khokhar JY; Tyndale RF
Toxicol Sci; 2012 Apr; 126(2):325-35. PubMed ID: 22287024
[TBL] [Abstract][Full Text] [Related]
27. Application of a source-to-outcome model for the assessment of health impacts from dietary exposures to insecticide residues.
Price PS; Schnelle KD; Cleveland CB; Bartels MJ; Hinderliter PM; Timchalk C; Poet TS
Regul Toxicol Pharmacol; 2011 Oct; 61(1):23-31. PubMed ID: 21651950
[TBL] [Abstract][Full Text] [Related]
28. The effect of plasma lipids on the pharmacokinetics of chlorpyrifos and the impact on interpretation of blood biomonitoring data.
Lowe ER; Poet TS; Rick DL; Marty MS; Mattsson JL; Timchalk C; Bartels MJ
Toxicol Sci; 2009 Apr; 108(2):258-72. PubMed ID: 19223661
[TBL] [Abstract][Full Text] [Related]
29. Acetylcholinesterase inhibition dose-response modeling for chlorpyrifos and chlorpyrifos-oxon.
Reiss R; Neal B; Lamb JC; Juberg DR
Regul Toxicol Pharmacol; 2012 Jun; 63(1):124-31. PubMed ID: 22446730
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of the chlorpyrifos metabolite 3,5,6-trichloro-2-pyridinol (TCPy) in rat saliva.
Smith JN; Wang J; Lin Y; Timchalk C
Toxicol Sci; 2010 Feb; 113(2):315-25. PubMed ID: 19920072
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of cholinesterase enzymes following a single dermal dose of chlorpyrifos and methyl parathion, alone and in combination, in pregnant rats.
Abu-Qare AW; Abdel-Rahman A; Brownie C; Kishk AM; Abou-Donia MB
J Toxicol Environ Health A; 2001 Jun; 63(3):173-89. PubMed ID: 11405414
[TBL] [Abstract][Full Text] [Related]
32. Physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus pesticide diazinon.
Poet TS; Kousba AA; Dennison SL; Timchalk C
Neurotoxicology; 2004 Dec; 25(6):1013-30. PubMed ID: 15474619
[TBL] [Abstract][Full Text] [Related]
33. Nonenzymatic functions of acetylcholinesterase splice variants in the developmental neurotoxicity of organophosphates: chlorpyrifos, chlorpyrifos oxon, and diazinon.
Jameson RR; Seidler FJ; Slotkin TA
Environ Health Perspect; 2007 Jan; 115(1):65-70. PubMed ID: 17366821
[TBL] [Abstract][Full Text] [Related]
34. Assessment of biochemical mechanisms of tolerance to chlorpyrifos in ancient and contemporary Daphnia pulicaria genotypes.
Simpson AM; Jeyasingh PD; Belden JB
Aquat Toxicol; 2017 Dec; 193():122-127. PubMed ID: 29059598
[TBL] [Abstract][Full Text] [Related]
35. Modeled estimates of chlorpyrifos exposure and dose for the Minnesota and Arizona NHEXAS populations.
Buck RJ; Ozkaynak H; Xue J; Zartarian VG; Hammerstrom K
J Expo Anal Environ Epidemiol; 2001; 11(3):253-68. PubMed ID: 11477522
[TBL] [Abstract][Full Text] [Related]
36. Esterases activity in the axolotl Ambystoma mexicanum exposed to chlorpyrifos and its implication to motor activity.
Robles-Mendoza C; Zúñiga-Lagunes SR; Ponce de León-Hill CA; Hernández-Soto J; Vanegas-Pérez C
Aquat Toxicol; 2011 Oct; 105(3-4):728-34. PubMed ID: 21996259
[TBL] [Abstract][Full Text] [Related]
37. Bayesian calibration of a physiologically based pharmacokinetic/pharmacodynamic model of carbaryl cholinesterase inhibition.
Nong A; Tan YM; Krolski ME; Wang J; Lunchick C; Conolly RB; Clewell HJ
J Toxicol Environ Health A; 2008; 71(20):1363-81. PubMed ID: 18704829
[TBL] [Abstract][Full Text] [Related]
38. Concentration-dependent binding of chlorpyrifos oxon to acetylcholinesterase.
Sultatos LG
Toxicol Sci; 2007 Nov; 100(1):128-35. PubMed ID: 17702992
[TBL] [Abstract][Full Text] [Related]
39. Oral and dermal absorption of chlorpyrifos: a human volunteer study.
Griffin P; Mason H; Heywood K; Cocker J
Occup Environ Med; 1999 Jan; 56(1):10-3. PubMed ID: 10341740
[TBL] [Abstract][Full Text] [Related]
40. Human red blood cell acetylcholinesterase inhibition as the appropriate and conservative surrogate endpoint for establishing chlorpyrifos reference dose.
Chen WL; Sheets JJ; Nolan RJ; Mattsson JL
Regul Toxicol Pharmacol; 1999 Feb; 29(1):15-22. PubMed ID: 10051415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
